FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087236585> ?p ?o ?g. }

• W2087236585 endingPage "865" @default.
• W2087236585 startingPage "856" @default.
• W2087236585 abstract "Purpose:XL647 is an oral small-molecule inhibitor of multiple receptor tyrosine kinases, including endothelial growth factor receptor (EGFR), vascular endothelial growth factor receptor 2, HER2 and Ephrin type-B receptor 4 (EphB4). We undertook an open-label, multi-institutional Phase II study to investigate the efficacy and safety of XL647 in treatment-naive non–small-cell lung cancer patients clinically enriched for the presence of EGFR mutations.Methods:Eligibility included patients with advanced-stage treatment-naive lung adenocarcinoma with a known sensitizing mutation of EGFR or patients with at least one of the following criteria: being Asian, female, or having minimal or no smoking history. Two dosing schedules were evaluated; in the “intermittent 5 & 9 dosing” cohort, XL647 350 mg for 5 days every 14 days was given; and in the “daily dosing” cohort, XL647 300 mg daily for 28 days was administered. Tumor EGFR mutation status was determined on available tissue. The primary end point was confirmed objective response rate.Results:Forty-one patients were treated on the intermittent 5 & 9 dosing- and 14 on the daily-dosing schedule. The majority of patients were eligible on the basis of smoking history. The response rate and progression-free survival for the two schedules combined were 20% and 5.3 months (90% confidence interval, 3.7–6.7), respectively. Thirty-eight patients (69%) had material available for mutation testing and 14 EGFR-sensitizing mutations were detected. The response rate and progression-free survival for EGFR-mutation–positive patients were 57% (8/14) and 9.3 months (90% confidence interval, 5.5–11.7). The toxicities were comparable between the two schedules; the most common adverse effects being diarrhea, nausea, and fatigue.Conclusions:XL647 administered on an intermittent or daily-dosing schedule demonstrated antitumor activity in patients with EGFR-activating mutations. The adverse-event profile was similar for the two dosing schedules. XL647 is an oral small-molecule inhibitor of multiple receptor tyrosine kinases, including endothelial growth factor receptor (EGFR), vascular endothelial growth factor receptor 2, HER2 and Ephrin type-B receptor 4 (EphB4). We undertook an open-label, multi-institutional Phase II study to investigate the efficacy and safety of XL647 in treatment-naive non–small-cell lung cancer patients clinically enriched for the presence of EGFR mutations. Eligibility included patients with advanced-stage treatment-naive lung adenocarcinoma with a known sensitizing mutation of EGFR or patients with at least one of the following criteria: being Asian, female, or having minimal or no smoking history. Two dosing schedules were evaluated; in the “intermittent 5 & 9 dosing” cohort, XL647 350 mg for 5 days every 14 days was given; and in the “daily dosing” cohort, XL647 300 mg daily for 28 days was administered. Tumor EGFR mutation status was determined on available tissue. The primary end point was confirmed objective response rate. Forty-one patients were treated on the intermittent 5 & 9 dosing- and 14 on the daily-dosing schedule. The majority of patients were eligible on the basis of smoking history. The response rate and progression-free survival for the two schedules combined were 20% and 5.3 months (90% confidence interval, 3.7–6.7), respectively. Thirty-eight patients (69%) had material available for mutation testing and 14 EGFR-sensitizing mutations were detected. The response rate and progression-free survival for EGFR-mutation–positive patients were 57% (8/14) and 9.3 months (90% confidence interval, 5.5–11.7). The toxicities were comparable between the two schedules; the most common adverse effects being diarrhea, nausea, and fatigue. XL647 administered on an intermittent or daily-dosing schedule demonstrated antitumor activity in patients with EGFR-activating mutations. The adverse-event profile was similar for the two dosing schedules." @default.
• W2087236585 created "2016-06-24" @default.
• W2087236585 creator A5001981163 @default.
• W2087236585 creator A5003723404 @default.
• W2087236585 creator A5003826371 @default.
• W2087236585 creator A5025836672 @default.
• W2087236585 creator A5030889960 @default.
• W2087236585 creator A5035120516 @default.
• W2087236585 creator A5036587861 @default.
• W2087236585 creator A5039791495 @default.
• W2087236585 creator A5039867739 @default.
• W2087236585 creator A5050489521 @default.
• W2087236585 creator A5052140189 @default.
• W2087236585 creator A5052336062 @default.
• W2087236585 creator A5057169108 @default.
• W2087236585 creator A5060033755 @default.
• W2087236585 creator A5068743826 @default.
• W2087236585 creator A5075877134 @default.
• W2087236585 creator A5081947660 @default.
• W2087236585 date "2012-05-01" @default.
• W2087236585 modified "2023-10-16" @default.
• W2087236585 title "Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer" @default.
• W2087236585 cites W1973312323 @default.
• W2087236585 cites W1998971866 @default.
• W2087236585 cites W2002937040 @default.
• W2087236585 cites W2003984225 @default.
• W2087236585 cites W2043696829 @default.
• W2087236585 cites W2063391304 @default.
• W2087236585 cites W2093613683 @default.
• W2087236585 cites W2095673635 @default.
• W2087236585 cites W2096786080 @default.
• W2087236585 cites W2097373408 @default.
• W2087236585 cites W2108042184 @default.
• W2087236585 cites W2108882588 @default.
• W2087236585 cites W2110024551 @default.
• W2087236585 cites W2111710483 @default.
• W2087236585 cites W2112602910 @default.
• W2087236585 cites W2115078104 @default.
• W2087236585 cites W2119358583 @default.
• W2087236585 cites W2125195105 @default.
• W2087236585 cites W2129360604 @default.
• W2087236585 cites W2132157071 @default.
• W2087236585 cites W2138089710 @default.
• W2087236585 cites W2139236349 @default.
• W2087236585 cites W2139248078 @default.
• W2087236585 cites W2155338842 @default.
• W2087236585 cites W2155971896 @default.
• W2087236585 cites W2160982674 @default.
• W2087236585 cites W2161821474 @default.
• W2087236585 cites W2166084034 @default.
• W2087236585 cites W2169816570 @default.
• W2087236585 cites W2299072364 @default.
• W2087236585 cites W2589149005 @default.
• W2087236585 doi "https://doi.org/10.1097/jto.0b013e31824c943f" @default.
• W2087236585 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22722787" @default.
• W2087236585 hasPublicationYear "2012" @default.
• W2087236585 type Work @default.
• W2087236585 sameAs 2087236585 @default.
• W2087236585 citedByCount "36" @default.
• W2087236585 countsByYear W20872365852012 @default.
• W2087236585 countsByYear W20872365852013 @default.
• W2087236585 countsByYear W20872365852014 @default.
• W2087236585 countsByYear W20872365852015 @default.
• W2087236585 countsByYear W20872365852016 @default.
• W2087236585 countsByYear W20872365852017 @default.
• W2087236585 countsByYear W20872365852018 @default.
• W2087236585 countsByYear W20872365852019 @default.
• W2087236585 countsByYear W20872365852020 @default.
• W2087236585 countsByYear W20872365852021 @default.
• W2087236585 countsByYear W20872365852022 @default.
• W2087236585 crossrefType "journal-article" @default.
• W2087236585 hasAuthorship W2087236585A5001981163 @default.
• W2087236585 hasAuthorship W2087236585A5003723404 @default.
• W2087236585 hasAuthorship W2087236585A5003826371 @default.
• W2087236585 hasAuthorship W2087236585A5025836672 @default.
• W2087236585 hasAuthorship W2087236585A5030889960 @default.
• W2087236585 hasAuthorship W2087236585A5035120516 @default.
• W2087236585 hasAuthorship W2087236585A5036587861 @default.
• W2087236585 hasAuthorship W2087236585A5039791495 @default.
• W2087236585 hasAuthorship W2087236585A5039867739 @default.
• W2087236585 hasAuthorship W2087236585A5050489521 @default.
• W2087236585 hasAuthorship W2087236585A5052140189 @default.
• W2087236585 hasAuthorship W2087236585A5052336062 @default.
• W2087236585 hasAuthorship W2087236585A5057169108 @default.
• W2087236585 hasAuthorship W2087236585A5060033755 @default.
• W2087236585 hasAuthorship W2087236585A5068743826 @default.
• W2087236585 hasAuthorship W2087236585A5075877134 @default.
• W2087236585 hasAuthorship W2087236585A5081947660 @default.
• W2087236585 hasBestOaLocation W20872365851 @default.
• W2087236585 hasConcept C121608353 @default.
• W2087236585 hasConcept C126322002 @default.
• W2087236585 hasConcept C143998085 @default.
• W2087236585 hasConcept C2776256026 @default.
• W2087236585 hasConcept C2777288759 @default.
• W2087236585 hasConcept C2778820342 @default.
• W2087236585 hasConcept C2779438470 @default.
• W2087236585 hasConcept C2781182431 @default.
• W2087236585 hasConcept C71924100 @default.

• next